Athira Pharma, Inc. — Form 10-Q Summary
Entity note: The filing provided is for Athira Pharma, Inc. (Nasdaq: ATHA), not Leonabio, Inc. It covers the quarter and six months ended June 30, 2023, and was filed August 10, 2023.
Business context and reporting period
Athira is a clinical-stage biopharmaceutical company developing small molecules for neurodegenerative disorders. Its lead candidate, fosgonimeton, is being studied for mild-to-moderate Alzheimer’s disease (AD). The company had no approved products and generated no product revenue.
Financial performance and liquidity
| Metric | Three months ended June 30, 2023 | Six months ended June 30, 2023 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $21.6 million | $42.9 million |
| General and administrative expense | $10.0 million | $18.5 million |
| Net loss | $29.6 million | $57.4 million |
| Net loss per share, basic and diluted | $0.78 | $1.51 |
| Net cash used in operating activities | Not stated for quarter | $50.5 million |
At June 30, 2023, cash and cash equivalents were $113.6 million; short- and long-term investments were $82.7 million; and cash, cash equivalents and investments totaled $196.3 million. Total assets were $208.0 million and total liabilities were $23.1 million. The filing reports no borrowings or financial debt. The accumulated deficit was $249.0 million.
Management estimated that available cash, cash equivalents and investments would fund operating expenses and capital expenditures through at least the 12 months following the filing date. The company reported no positive operating cash flow and expects to need substantial additional funding.
Material changes versus the prior comparable period
- Second-quarter operating expenses rose 34% to $31.6 million year over year; R&D increased 46%, primarily due to fosgonimeton trial activity, manufacturing development, and personnel costs.
- Second-quarter net loss increased 22% to $29.6 million. For the first six months, net loss increased 27% to $57.4 million.
- Six-month operating cash use increased to $50.5 million from $35.2 million in 2022.
- Higher interest and investment income partly offset expenses: other income, net, was $2.0 million for the quarter and $3.8 million for the six months.
- Cash and investments totaled $196.3 million at June 30, down from $245.2 million at December 31, 2022. The company had not sold shares under its $75 million at-the-market offering program.
Outlook, clinical program, risks, and contingencies
- Fosgonimeton: ACT-AD’s primary and secondary endpoints were not met in the planned analysis. Post hoc subgroup findings among participants not taking background acetylcholinesterase inhibitors (AChEIs) were not statistically significant and do not establish efficacy.
- LIFT-AD: The company amended the Phase 2/3 trial to focus on participants not taking AChEIs and, in May 2023, to focus enrollment and primary analysis on the 40 mg dose, discontinuing further enrollment in the 70 mg arm. Topline results were expected in the second half of 2024. An independent monitoring committee had recommended continuing the trial after an interim analysis; this is not evidence of trial success.
- Regulatory discussion: In July 2023, after quarter-end, Athira held an end-of-Phase 2 meeting with FDA. FDA emphasized showing effects on both cognition and function. The filing does not report an FDA approval or a commitment to a specific development path.
- Research-integrity and legal matters: A board special committee found that former CEO Leen Kawas altered images in her dissertation and at least four research papers; it also reported that challenged papers were cited in certain company materials and that the WSU dihexa patent licensed to Athira incorporated certain altered images. WSU’s review remained ongoing. DOJ had issued a Civil Investigative Demand and the SEC had issued a subpoena; Athira said it was cooperating with both.
- Settlement and other litigation: Athira recorded a $10 million expense and liability for a proposed securities class-action settlement. The settlement remained subject to court approval. Consolidated shareholder derivative actions were stayed; the company said it believed its reserves for that matter were adequate.
- Funding and dilution: The $75 million ATM program was available but unused as of the filing. Additional equity financing could dilute shareholders; debt or collaboration financing could impose restrictions or require the company to give up rights.
- Other principal risks: Clinical failure or delay, patient enrollment and retention, competition, reliance on contract manufacturers and research organizations, uncertain regulatory and reimbursement outcomes, intellectual-property challenges, and the potential effects of the investigations on reputation and licensed rights.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing identifies Athira Pharma, Inc., not Leonabio, Inc.
- Review LIFT-AD enrollment, protocol, statistical analysis plan, and 2024 topline timing; distinguish exploratory or post hoc findings from prespecified trial results.
- Track the status and outcome of the WSU review, DOJ and SEC inquiries, securities settlement approval, and derivative litigation.
- Assess cash burn against the stated 12-month runway, the timing of future financing needs, and any use of the ATM program.
- Consider potential dilution from equity awards: 7.7 million options and restricted stock units were outstanding at June 30, 2023, in addition to shares available for future grants.